Dynamics of Serum Thymidine Kinase 1 at the First Cycle of Neoadjuvant Chemotherapy Predicts Outcome of Disease in Estrogen-Receptor-Positive Breast Cancer

Pathologic complete response (pCR) predicts the long-term outcome of neoadjuvantly treated (NAC) breast cancer (BC) but is reached in <10% of hormone-receptor-positive patients. Biomarkers enabling adjustment or interruption of an ineffective therapy are desired. Here, we evaluated whether change...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Bernhard Tribukait
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	circulating thymidine kinase 1 cell loss biomarker early treatment response breast cancer Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/43f23180dbdf4735be547d759721b756
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:43f23180dbdf4735be547d759721b756
record_format	dspace
spelling	oai:doaj.org-article:43f23180dbdf4735be547d759721b7562021-11-11T15:32:04ZDynamics of Serum Thymidine Kinase 1 at the First Cycle of Neoadjuvant Chemotherapy Predicts Outcome of Disease in Estrogen-Receptor-Positive Breast Cancer10.3390/cancers132154422072-6694https://doaj.org/article/43f23180dbdf4735be547d759721b7562021-10-01T00:00:00Zhttps://www.mdpi.com/2072-6694/13/21/5442https://doaj.org/toc/2072-6694Pathologic complete response (pCR) predicts the long-term outcome of neoadjuvantly treated (NAC) breast cancer (BC) but is reached in <10% of hormone-receptor-positive patients. Biomarkers enabling adjustment or interruption of an ineffective therapy are desired. Here, we evaluated whether changes in the serum concentration of thymidine kinase 1 (sTK1) during NAC could be utilized as a biomarker. In the PROMIX trial, women with localized HER2- BC received neoadjuvant epirubicin/docetaxel in six cycles. sTK1 was measured with an ELISA in 54 patients at cycles 1–4 and in an additional 77 patients before and 48 h after treatment 1. Treatment resulted in a 2-fold increase of sTK1 before and a 3-fold increase 48 h after the cycles, except for the first cycle, where half of the patients reacted with a significant decrease and the other half with an increase of sTK1. In Kaplan–Meier estimates of ER+ patients divided by the median of the post/pre-treatment sTK1 ratio at the first treatment cycle, OS was 97.7% and 78% (<i>p</i> = 0.005), and DFS was 90.7% and 68% (<i>p</i> = 0.006), respectively. Thus, the response of sTK1 at the first cycle of chemotherapy could be used both as an early biomarker for the guidance of chemotherapy and for the study of inherent tumor chemo-sensitivity, which could predict long-term outcome prior to therapy.Bernhard TribukaitMDPI AGarticlecirculating thymidine kinase 1cell lossbiomarkerearly treatment responsebreast cancerNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCancers, Vol 13, Iss 5442, p 5442 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	circulating thymidine kinase 1 cell loss biomarker early treatment response breast cancer Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	circulating thymidine kinase 1 cell loss biomarker early treatment response breast cancer Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Bernhard Tribukait Dynamics of Serum Thymidine Kinase 1 at the First Cycle of Neoadjuvant Chemotherapy Predicts Outcome of Disease in Estrogen-Receptor-Positive Breast Cancer
description	Pathologic complete response (pCR) predicts the long-term outcome of neoadjuvantly treated (NAC) breast cancer (BC) but is reached in <10% of hormone-receptor-positive patients. Biomarkers enabling adjustment or interruption of an ineffective therapy are desired. Here, we evaluated whether changes in the serum concentration of thymidine kinase 1 (sTK1) during NAC could be utilized as a biomarker. In the PROMIX trial, women with localized HER2- BC received neoadjuvant epirubicin/docetaxel in six cycles. sTK1 was measured with an ELISA in 54 patients at cycles 1–4 and in an additional 77 patients before and 48 h after treatment 1. Treatment resulted in a 2-fold increase of sTK1 before and a 3-fold increase 48 h after the cycles, except for the first cycle, where half of the patients reacted with a significant decrease and the other half with an increase of sTK1. In Kaplan–Meier estimates of ER+ patients divided by the median of the post/pre-treatment sTK1 ratio at the first treatment cycle, OS was 97.7% and 78% (<i>p</i> = 0.005), and DFS was 90.7% and 68% (<i>p</i> = 0.006), respectively. Thus, the response of sTK1 at the first cycle of chemotherapy could be used both as an early biomarker for the guidance of chemotherapy and for the study of inherent tumor chemo-sensitivity, which could predict long-term outcome prior to therapy.
format	article
author	Bernhard Tribukait
author_facet	Bernhard Tribukait
author_sort	Bernhard Tribukait
title	Dynamics of Serum Thymidine Kinase 1 at the First Cycle of Neoadjuvant Chemotherapy Predicts Outcome of Disease in Estrogen-Receptor-Positive Breast Cancer
title_short	Dynamics of Serum Thymidine Kinase 1 at the First Cycle of Neoadjuvant Chemotherapy Predicts Outcome of Disease in Estrogen-Receptor-Positive Breast Cancer
title_full	Dynamics of Serum Thymidine Kinase 1 at the First Cycle of Neoadjuvant Chemotherapy Predicts Outcome of Disease in Estrogen-Receptor-Positive Breast Cancer
title_fullStr	Dynamics of Serum Thymidine Kinase 1 at the First Cycle of Neoadjuvant Chemotherapy Predicts Outcome of Disease in Estrogen-Receptor-Positive Breast Cancer
title_full_unstemmed	Dynamics of Serum Thymidine Kinase 1 at the First Cycle of Neoadjuvant Chemotherapy Predicts Outcome of Disease in Estrogen-Receptor-Positive Breast Cancer
title_sort	dynamics of serum thymidine kinase 1 at the first cycle of neoadjuvant chemotherapy predicts outcome of disease in estrogen-receptor-positive breast cancer
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/43f23180dbdf4735be547d759721b756
work_keys_str_mv	AT bernhardtribukait dynamicsofserumthymidinekinase1atthefirstcycleofneoadjuvantchemotherapypredictsoutcomeofdiseaseinestrogenreceptorpositivebreastcancer
_version_	1718435235149905920

Dynamics of Serum Thymidine Kinase 1 at the First Cycle of Neoadjuvant Chemotherapy Predicts Outcome of Disease in Estrogen-Receptor-Positive Breast Cancer

Ejemplares similares